CD4+CD25(high), CD8+CD28-cells and thyroid autoantibodies in breast cancer patients

Basit Öğe Kaydı
dc.authorid0000-0002-4075-6692en_US
dc.contributor.authorBilgi, Oguz
dc.contributor.authorKaragoz, Bulent
dc.contributor.authorTurken, Orhan
dc.contributor.authorGultepe, Mustafa
dc.contributor.authorOzgun, Alpaslan
dc.contributor.authorTuncel, Tolga
dc.contributor.authorEmirzeoglu, Levent
dc.contributor.authorCelik, Serkan
dc.contributor.authorMuftuoglu, Tuba
dc.contributor.authorKandemir, Emin Gokhan
dc.date.accessioned2024-07-12T21:45:33Z
dc.date.available2024-07-12T21:45:33Z
dc.date.issued2014en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractAim of the study: To investigate the percentage of CD4+CD25(high) cells (including Treg cells) and CD8+CD28- cells in breast cancer patients with and without high levels of autoimmune thyroid antibodies. Material and methods: Thirty-five women with breast cancer (9 of them having high thyroid antibodies) and fourteen healthy subjects were enrolled in this study. Flow cytometry was used to count CD4+CD25(high) cells and CD8+CD28- suppressive cells (CD8 cell subtypes). Results: In the patient group, the percentage of CD28 cells in CD8+ lymphocytes were higher [67.50% (55.1180.33) vs. 51.56% (42.5766.38); p = 0.021] and the percentage of CD28+CD45RO- cells (memory cells) in CD8+ lymphocytes were lower than in the control group. CD4+CD25(high) cell percentage in CD4+ lymphocytes was elevated in the patient group [6.44% (4.528.74) vs. 2.97% (1.724.34); p < 0.001]. When the cytometric parameters were compared between patients (with high vs. normal thyroid antibodies), the distribution of CD8+ cell subgroups was also similar. CD4+CD25high cells among CD4+ lymphocytes were decreased in patients with high levels of thyroid antibodies [5.19% (3.426.17) vs. 6.99% (4.829.95); p = 0.043]. Conclusions: CD4+CD25(high) cells may play a role in autoimmunity of breast cancer patients, and may be a predictive marker. Advanced studies which evaluate the possible links between regulatory cells and autoimmunity should be established in cancer patients.en_US
dc.identifier.doi10.5114/ceji.2014.45945
dc.identifier.endpage344en_US
dc.identifier.issn1426-3912
dc.identifier.issn1644-4124
dc.identifier.issue3en_US
dc.identifier.pmid26155145en_US
dc.identifier.scopus2-s2.0-84908013311en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage338en_US
dc.identifier.urihttps://dx.doi.org/10.5114/ceji.2014.45945
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7841
dc.identifier.volume39en_US
dc.identifier.wosWOS:000344202400012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTERMEDIA PUBLISHING HOUSE LTDen_US
dc.relation.ispartofCENTRAL EUROPEAN JOURNAL OF IMMUNOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY00489
dc.subjectbreast canceren_US
dc.subjectTreg cellsen_US
dc.subjectautoimmunityen_US
dc.subjectthyroid antibodyen_US
dc.titleCD4+CD25(high), CD8+CD28-cells and thyroid autoantibodies in breast cancer patientsen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu